Here is the design of a clinical trial:

Official Title: Precision Medicine Phase II Study Evaluating the Efficacy of a Double Immunotherapy by Durvalumab and Tremelimumab Combined With Olaparib in Patients With Solid Cancers and Carriers of Homologous Recombination Repair Genes Mutation in Response or Stable After Olaparib Treatment

Included conditions:
- Immunotherapy

Study Armgroups:
- {'label': 'GUIDE2REPAIR patients', 'type': 'EXPERIMENTAL', 'description': 'olaparib + immunotherapy (durvalumab + tremelimumab) during 4 months followed by durvalumab alone as maintenance in patients with solid cancer and in response or stable after prior molecular target therapy by olaparib based on molecular sequencing.', 'interventionNames': ['Drug: olaparib, durvalumab, tremelimumab']}

Interventions:
- {'type': 'DRUG', 'name': 'olaparib, durvalumab, tremelimumab', 'description': 'STEP 1:\n\nOlaparib 300 mg BID during 8 weeks. Olaparib tablets should be taken at the same time each day, approximately 12 hours apart with one glass of water. The tablets should be swallowed whole and not chewed, crushed, dissolved or divided. Olaparib tablets can be taken with or without food\n\nSTEP 2:\n\nOlaparib 300 mg during 4 months as per same requirement as below. Durvalumab 1500 mg plus tremelimumab 75 mg via IV infusion Q4W, starting on Week 0, for up to a maximum of 4 doses followed by durvalumab monotherapy 1500 mg via IV infusion Q4W, starting 4 weeks after the last infusion of the combination and in response or stable after prior molecular target therapy by olaparib based on molecular sequencing.', 'armGroupLabels': ['GUIDE2REPAIR patients']}

Primary Outcomes:
- {'measure': 'Safety Assessments: progression free survival', 'description': 'progression free survival', 'timeFrame': '6 months after the initiation of immunotherapy for all cohorts excepted for ovarian cohort where PFS will be evaluated at 12 months.'}

Please estimate the sample size based on the assumption: 
One-sided alpha risk = 10%, power = 90%, expected rate of patients non-evaluable for the primary endpoint is 5%.
Sample size calculation
          Sample size was determined using an AâHernâs single stage design. The primary endpoint is progression PFS. It will be evaluated at 6âmonths (except for ovarian cancer with an evaluation at 18âmonths given the results of olaparib in SOLO-2 trial). The hypotheses are the following:
one-sided alpha risk =10%, a powerâ=â90%,the expected rate of patients stable or in response after 6âweeks of olaparib is 80%,the expected rate of patients non-evaluable the primary endpoint is 5%,P0 and P1 are determined using hypotheses detailed above.
          P0 is the highest level of inefficacy for which the new treatment will be rejected (maximal inefficacity). P1 defines the minimum required level of efficacy. The design of the trial focuses on demonstrating that this level is plausible given that the trial results and the efficacy is greater than the first proportion, P0. Taking into account these hypotheses: 270 patients will be included in the study, and at least 213 are required for statistical analyses. At the end the study, analysis of the primary endpoint will be performed on evaluable patients who were in response or stable after 8âweeks of olaparib.